Further studies are needed to investigate whether and how FGF2 inhibitor SU5402 can prevent the antidepressant effect of FGF2 and provide more experimental evidence for the relevance of FGF2/FGFR pathway in inflammation-induced depression. This evidence concerns the gene FGF2 and depressive symptom measurement.